Replies to post #5556 on Anavex Life Sciences Corp (AVXL)

[JB3729]

Our newly appointed Director received 200,000 options. He is a patent attorney -

PR -

NEW YORK, NY – June 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Steffen Thomas, PhD, to its Board of Directors. Dr. Thomas has 15 years of experience in intellectual property, patent law and proprietary technology rights as well as significant expertise in small molecule pharmaceuticals.

Dr. Thomas is currently a patent attorney, European patent attorney and European trademark attorney at Epping Hermann Fischer, a major European intellectual property law firm. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, which was acquired by Takeda in 2011 for approximately USD $10 billion.

Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry.

“We are pleased to welcome Dr. Thomas to our Board,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We believe Dr. Thomas’ expertise in intellectual property as well as his pharmaceutical industry insight will be extremely beneficial as we are advancing our pipeline.”

Dr. Thomas holds MS and PhD degrees in Chemistry from the University of Munich.


From 8-K -

Effective June 15, 2015 (the “Effective Date” ), the board of directors (the “Board” ) of Anavex Life Sciences Corp., a Nevada corporation (the “Company” ), appointed Steffen Thomas, PhD, to serve as a member of the Board until his successor is duly elected, qualified and seated or until his earlier resignation or removal.

In addition to being a member of the Board, it is anticipated that Dr. Thomas will serve on the Audit Committee, effective as of the Effective Date. As compensation for his services, the Company granted Dr. Thomas options to purchase two hundred thousand (200,000) shares of common stock in the Company, said options to vest annually over a three year period commencing on the first anniversary of the Effective Date.

The Company has not entered into any transactions with Dr. Thomas that would require disclosure pursuant to Item 404(a) of Regulation S-K under the Exchange Act of 1934, as amended.